You are here

Reprogramming intratumoral Treg cells by morpholino-mediated splicing of FOXP3 for cancer immunotherapy

Authors: 
Li Y, Singh N, Dong C, Sharma S, Zhou Z, Du J, Haouili M, Jiao Y, Hopewell E, Liu Y, Opyrchal M, Zhang X, Zhou B, Lu X
Citation: 
Sci Immunol. 2025 Aug 22;10(110):eadr9933. doi: 10.1126/sciimmunol.adr9933. Epub 2025 Aug 22. PMID: 40845126.
Abstract: 
Regulatory T cells (Treg cells) represent a primary barrier to the development of effective antitumor immunity. Here, we report that reprogramming Treg cells by shifting the expression of FOXP3 from its full-length isoform (FOXP3FL) to a short isoform with exon 2 skipped (FOXP3dE2) promotes CD8 T cell-mediated antitumor immunity. FOXP3dE2 mRNA expression in triple-negative breast cancer tissue positively correlated with overall patient survival. Mice expressing only the FOXP3dE2 isoform were resistant to the development of multiple types of tumors. Tumor-infiltrating Treg cells expressing the FOXP3dE2 isoform exhibited lower immunosuppressive activity and promoted CD8 T cell activation. In addition, we designed a morpholino oligo to induce FOXP3 exon 2 skipping, which similarly enhanced antitumor activity in mouse tumor models and the killing capacity of autologous tumor-infiltrating T cells against patient-derived tumor organoids. Our results suggest that promoting FOXP3dE2 expression reprograms Treg cells to T helper-like cells, thereby enhancing antitumor immunity.
Epub: 
Not Epub
Organism or Cell Type: 
PMO-treated Treg splenic cells isolated from wild type or Foxp3dE2 mice co-cultured with human breast cancer and human colorectal cancer patient-derived tumor organoids
Delivery Method: 
Vivo-Morpholino